URSODIOL
Cholan-24-oic acid, 3,7-dihydroxy-, 3-α, 5-β, 7-β)-
URSODIOL 列于欧盟 CosIng 清单,但本页尚未关联任何直接的附件记录。
按市场划分的监管证据
此处跟踪的 13 个市场均未导入该成分的规则。
这描述的是本清单,而非法律。没有已导入的规则并不能证明某成分获准使用:规则可能以其他名称或标识符存在,或存在于尚未在此导入的数据集中。
URSODIOL 的清单详情
INCI 名称
URSODIOL
说明
Cholan-24-oic acid, 3,7-dihydroxy-, 3-α, 5-β, 7-β)-
URSODIOL 的附件记录
关键数据
- SKIN CONDITIONING
Maintaining the skin in good condition.
- SKIN PROTECTING
Helping to avoid harmful effects to the skin from external factors.
化学身份与性质

Ursodeoxycholic Acid
Ursodeoxycholic acid is a bile acid found in the bile of bears (Ursidae) as a conjugate with taurine. Used therapeutically, it prevents the synthesis and absorption of cholesterol and can lead to the dissolution of gallstones. It has a role as a mouse metabolite and a human metabolite. It is a C24-steroid, a dihydroxy-5beta-cholanic acid and a bile acid. It is a conjugate acid of an ursodeoxycholate. — ChEBI
- IUPAC 名称
- (4R)-4-[(3R,5S,7S,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid
- 分子式
- C24H40O4
- 分子量
- 392.6 g/mol
- 精确质量
- 392.29265975 Da
- XLogP3
- 4.9
- 拓扑极性表面积
- 77.8 Ų
- 氢键供体
- 3
- 氢键受体
- 4
- 共价单元
- 1
- 已定义的立体中心
- 10
又称
另有 16 个已报告名称
外部数据库标识符
- ChEBI:CHEBI:9907
- ChEMBL:CHEMBL1551
- EPA DTXSID:DTXSID6023731
- PubMed:38244730
- PubMed:38104874
- PubMed:37968239
- PubMed:36473578
- PubMed:36470304
- PubMed:34461081
- PubMed:34155936
- PubMed:34079822
- PubMed:33568795
- PubMed:32679164
- PubMed:32198087
- PubMed:31299240
来自其他科学数据库的证据
NIH PubChem PUG-View
Attributed physical-property, hazard, environmental and use annotations.
- LogP: 3 来源: DrugBank
- LogP: 3.00 来源: Human Metabolome Database (HMDB)
- Melting Point: 200-205 来源: DrugBank
- Melting Point: 203 °C 来源: Human Metabolome Database (HMDB)
- Physical Description: Solid 来源: Human Metabolome Database (HMDB)
- Solubility: 0.02 mg/mL 来源: Human Metabolome Database (HMDB)
- Note: This chemical does not meet GHS hazard criteria for 4.5% (2 of 44) of reports. 来源: European Chemicals Agency (ECHA)
- Signal: Warning 来源: European Chemicals Agency (ECHA)
- GHS Hazard Statements: H315 (95.5%): Causes skin irritation [Warning Skin corrosion/irritation]; H319 (95.5%): Causes serious eye irritation [Warning Serious eye damage/eye irritation] 来源: European Chemicals Agency (ECHA)
- Precautionary Statement Codes: P264, P264+P265, P280, P302+P352, P305+P351+P338, P321, P332+P317, P337+P317, and P362+P364 (click each P-code to see the statement) 来源: European Chemicals Agency (ECHA)
- ECHA C&L Notifications Summary: Aggregated GHS information provided per 44 reports by companies from 4 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.; Reported as not meeting GHS hazard criteria per 2 of 44 reports by companies.; There are 3 notifications provided by 42 of 44 reports by companies with hazard statement code(s).; Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website. 来源: European Chemicals Agency (ECHA)
- Toxicity Summary: UDCA has been shown to have potentially toxic molecular properties. UDCA breaks down into toxic lithocholic acid. After being absorbed in the small intestine, UDCA undergoes hepatic conjugation. Beyond conjugation, UDCA does not experience further breakdown by the liver or intestinal mucosa. It becomes oxidized or reduced, yielding either 7-keto-lithocholic acid or lithocholic acid. Litcholic acid can be toxic to liver cells and even cause liver failure in those with compromised sulfation. It also leads to segmental bile duct injury, hepatocyte failure, and death. 来源: StatPearls
- Uses: Use (kg; approx.) in Germany (2009): >10000; Use (kg) in USA (2002): 6870; Consumption (g per capita; approx.) in Germany (2009): 0.122; Consumption (g per capita) in the USA (2002): 0.0244; Excretion rate: 1; Calculated removal (%): 73.4 来源: NORMAN Suspect List Exchange
映射方: Existing checksum-valid CAS to unique PubChem CID match. 检索时间: 2026-08-31. 打开来源记录
科学分类和危害注释仅提供背景信息,不能取代上方所示针对具体市场的监管决定。
其他来源的覆盖范围和匹配状态
| 来源 | 结果 | 已检查 |
|---|---|---|
| NIH PubChem PUG-View | 精确匹配 | 2026-08-31 |
已记录的无匹配结果是该来源已被检查的有效证据;这并不表示该物质在别处不存在。
于 2026-08-31 通过校验和有效的 CAS 匹配从美国国立卫生研究院 (NIH) PubChem 检索。化学性质不能取代本页的监管决定。
欧盟官方成分名称证据
该成分名称与 2025 年欧盟官方通用成分名称词汇表完全匹配。
相关清单证据
配方功能重叠的成分
其他官方和科学来源
11 个可用于核查此身份的外部数据库
每个链接都会在该来源中搜索此身份。 各来源是什么及其法律效力
URSODIOL 在 CosIng 清单中的呈现方式
CosIng 清单将 URSODIOL 列为化妆品成分,本页将其关联到 0 条附件记录。清单条目记录名称和标识符,而附件记录显示该物质在欧盟化妆品法规中被禁用、限用或列入准用清单的情况。
在官方数据中,URSODIOL 还被标记了 2 项化妆品功能。功能标识描述预期用途,但不能取代在配方或标签工作之前对关联附件记录的监管审查。